Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Shares Upgraded to Outperform by Evercore ISI

NEW YORK – Investment bank Evercore ISI on Tuesday upgraded shares of Twist Bioscience to Outperform, citing management's response to a recent report from a short seller that dragged down its share price toward the end of 2022.

"We believe the tides are changing and have become incrementally positive on this name," analyst Vijay Kumar wrote in a note to investors. He set a price target of $36 for shares of the synthetic DNA maker, approximately 50 percent higher than Friday's closing price. In afternoon trading on the Nasdaq, Twist's stock price was flat at $23.41.

Shares of Twist fell approximately 75 percent over 2022, Kumar noted, capped off by a 20 percent dip in November spurred by a short seller's report raising concerns about the firm's accounting practices and new factory in Oregon, slated to come online this quarter. "While there has been negative sentiment around [Twist] into year's end, we thought management did a good job walking through the bear concerns, which gives us confidence in fiscal year 2023 and beyond," he wrote.

Specifically, the firm addressed two of the three "material weaknesses brought up by [accounting firm] PricewaterhouseCoopers" and hosted a tour of its factory in late November, Kumar said. "Without this overhang, we expect investors to value Twist based on fundamentals."

The new valuation equates to approximately seven times the firm's expected calendar year 2023 revenues and 17 times its anticipated gross profit.

For fiscal year 2023, which began in October, Twist expects total revenues in the range of $261 million to $269 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.